Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-08

Clinical Trial Update: A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating MK-8521 for Type 2 Diabetes Mellitus was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-8521

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type II Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2018-03-08